2197 — Clover Biopharmaceuticals Cashflow Statement
0.000.00%
- HK$441.00m
- -HK$22.88m
- CNY39.26m
Annual cashflow statement for Clover Biopharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -48.6 | -913 | -6,016 | -2,452 | -139 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 9.46 | 31.5 | 178 | 636 | 1,814 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 10.1 | 1,353 | 4,896 | 65.1 | -2,478 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -26.6 | 477 | -918 | -1,691 | -728 |
Capital Expenditures | -6.82 | -114 | -80.3 | -106 | -9.18 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 4.22 | -280 | 192 | 68.1 | 3.02 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.6 | -394 | 112 | -37.5 | -6.16 |
Financing Cash Flow Items | 0 | -0.327 | -159 | -235 | -130 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 142 | 317 | 3,057 | 483 | -142 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 113 | 367 | 2,251 | -1,160 | -872 |